Breath test may predict who responds to common asthma drug for chronic cough
NCT ID NCT06590740
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at 1000 adults with chronic dry or nighttime cough to find a cutoff value for a breath test called FeNO that can predict whether they will respond to the asthma medication budesonide-formoterol. Participants took the drug twice daily for 8 weeks, and their cough improvement was measured. The goal is to help doctors quickly identify patients who are likely to benefit from this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Budesonide-formoterol (Symbicort)
What this could lead to
If successful, this could help doctors quickly identify which chronic cough patients are likely to benefit from budesonide-formoterol, improving treatment decisions.
What could go wrong
This is a completed study focused on finding a diagnostic cutoff, not testing a new treatment. The results may not apply to all patients or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COUGH-VARIANT ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100029, China
-
Research Site
Beijing, 100034, China
-
Research Site
Benxi, 117000, China
-
Research Site
Chengdu, 610014, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400000, China
-
Research Site
Dongguan, CN-523326, China
-
Research Site
Fenyang, 032299, China
-
Research Site
Fuzhou, 350005, China
-
Research Site
Guangzhou, 510000, China
-
Research Site
Guangzhou, 510163, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Guiyang, 550002, China
-
Research Site
Heifei, 230011, China
-
Research Site
Heze, 274400, China
-
Research Site
Huizhou, 516002, China
-
Research Site
Jiaxing, 314001, China
-
Research Site
Jinhua, 321000, China
-
Research Site
Liuzhou, 545006, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanjing, 211100, China
-
Research Site
Nanyang, 473000, China
-
Research Site
Quanzhou, 362000, China
-
Research Site
Shanghai, 201114, China
-
Research Site
Shanghai, 310000, China
-
Research Site
Shangqiu, 476100, China
-
Research Site
Shenzhen, 518020, China
-
Research Site
Shijiazhuang, 050001, China
-
Research Site
Suzhou, 657299, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Taiyuan, 030032, China
-
Research Site
Weifang, 261000, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wenzhou, 325027, China
-
Research Site
Xi'an, 710006, China
-
Research Site
Xiangtan, 411228, China
-
Research Site
Yantai, 264000, China
-
Research Site
Zhengzhou, 450000, China
-
Research Site
Zunyi, 563100, China